Want to see JP:4896 full AI Analyst Report?
Top Page
K Pharma,Inc.
(4896)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥800.00
▲(22.89% Upside)
Action:Reiterated
Date:08/07/26
The score is held down primarily by weak financial performance—zero revenue in recent periods, large losses, ongoing cash burn, and rising leverage with shrinking equity. Technicals provide a modest offset with neutral-to-slightly positive momentum and price holding near/above key moving averages. Valuation remains a concern because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Prior Revenue and Profitability
The 2023 results show that K Pharma has previously generated meaningful revenue and positive net income, demonstrating some historical ability to commercialize its business. Re-establishing that operating base would provide a credible foundation for recovery if revenue-generating activity resumes.
Negative Factors
Zero Revenue and Large Losses
The absence of reported revenue in the latest periods removes the normal operating base needed to fund research and corporate costs. Large operating and net losses therefore indicate that profitability recovery depends on restarting commercialization or securing other durable sources of funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Prior Revenue and Profitability
The 2023 results show that K Pharma has previously generated meaningful revenue and positive net income, demonstrating some historical ability to commercialize its business. Re-establishing that operating base would provide a credible foundation for recovery if revenue-generating activity resumes.
Read all positive factors
K Pharma,Inc. (4896) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.44B
Dividend YieldN/A
Average Volume (3M)15.13K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS Growth-20.34%
CountryJP
Employees20
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-20.84
Shares Outstanding11,622,600
10 Day Avg. Volume21,000
30 Day Avg. Volume15,130
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-8.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
K Pharma,Inc. Business Overview & Revenue Model
Company Description
K Pharma, Inc., headquartered in Minato, Japan, was established in 2016 and operates within the Japanese market. The company is dedicated to the research, development, production, and sale of both regenerative medicines and pharmaceutical products...
K Pharma,Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.00B | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 910.00M | 0.00 | -6.80M |
| EBITDA | -983.19M | -844.10M | 366.06M | -390.53M | -222.31M |
| Net Income | -993.23M | -846.46M | 260.33M | -392.43M | -228.72M |
Balance Sheet | |||||
| Total Assets | 2.94B | 2.35B | 3.31B | 1.37B | 205.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.79B | 2.27B | 3.27B | 1.34B | 188.78M |
| Total Debt | 1.50B | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.67B | 94.76M | 209.13M | 38.30M | 26.88M |
| Stockholders Equity | 1.27B | 2.26B | 3.10B | 1.34B | 178.89M |
Cash Flow | |||||
| Free Cash Flow | -929.19M | -998.21M | 444.62M | -393.44M | -196.32M |
| Operating Cash Flow | -918.00M | -983.72M | 454.43M | -363.48M | -196.32M |
| Investing Cash Flow | -54.68M | -14.49M | -11.10M | -32.74M | -250.00K |
| Financing Cash Flow | 1.50B | 0.00 | 1.49B | 1.54B | 368.20M |
K Pharma,Inc. Technical Analysis
Positive
651.00
Price Trends
743.24
Positive
726.84
Positive
721.53
Positive
Market Momentum
19.62
Negative
65.33
Neutral
60.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4896, the sentiment is Positive. The current price of 651 is below the 20-day moving average (MA) of 777.30, below the 50-day MA of 743.24, and below the 200-day MA of 721.53, indicating a bullish trend. The MACD of 19.62 indicates Negative momentum. The RSI at 65.33 is Neutral, neither overbought nor oversold. The STOCH value of 60.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4896.
K Pharma,Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥7.80B | 52.23 | ― | 1.51% | 4.85% | -40.57% | |
58 Neutral | ¥6.87B | 97.19 | ― | 1.46% | -7.13% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ¥9.17B | -8.54 | ― | ― | -19.99% | 16.36% | |
47 Neutral | ¥9.44B | -9.06 | ― | ― | ― | -20.34% | |
46 Neutral | ¥7.08B | -3.99 | ― | ― | -94.55% | -6.51% | |
44 Neutral | ¥8.53B | -7.46 | ― | ― | -56.16% | 3.12% |
* General Sector Average
JP:4896
K Pharma,Inc.
819.00
137.00
20.09%
JP:4583
Chiome Bioscience Inc.
99.00
-41.00
-29.29%
JP:4594
BrightPath Biotherapeutics Co.Ltd.
52.00
-28.00
-35.00%
JP:4880
CellSource Co., Ltd.
343.00
-257.97
-42.93%
JP:7096
StemCell Institute
761.00
-195.00
-20.40%
JP:7776
CellSeed Inc.
223.00
-259.00
-53.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.